YGION Biomedical secures €15M Series A for personalized cancer immunotherapies

YGION Biomedical GmbH, a Vienna-based company, has successfully concluded a Series A financing round, securing €15 million from an Austrian private trust. The funds will be allocated to advance the development of YGION's YGNITETM technology platform and propel its leading program, YG-01, through preclinical and clinical phases.

Established in 2022, YGION Biomedical boasts a team of seasoned biotech professionals and entrepreneurs. Their mission is to create individualized, "plug-and-play" cancer vaccines. Using a proprietary array of technologies, YGION aims to identify, produce, and deliver relevant peptide neoepitopes. This results in a highly potent and precise activation of a patient's immune system, providing a safe and effective treatment.

Dr. Wolfgang Fischl, YGION’s CEO, expressed excitement over the new funding, viewing it as a significant endorsement of their innovative approach. He stated, "We are on the verge of a breakthrough in personalized cancer treatments. This financing validates our unique methodology, and we are grateful for our investors' support. This backing allows us to move closer to clinical validation of our technology. As we continue to demonstrate our approach's efficacy, we welcome additional investors and collaborators interested in our groundbreaking work."

Dr. Geert Mudde, YGION's CTO, echoed this optimism, emphasizing the potential of their technology to deliver simple, safe, and effective cancer vaccines. He highlighted the YGNITETM platform's unique capability to identify, select, and synthesize relevant neoantigens. Combined with the CARGONAUTTM immune-modulating carrier, it induces a powerful, cell-mediated tumor-specific response, effectively targeting and eliminating malignant cells with unmatched safety.

YGION’s primary program, YG-01, is currently in the preclinical development stage. The company is dedicated to advancing its research and bringing its innovative cancer treatments to clinical trials.

YGION Biomedical GmbH operates out of Vienna, Austria, as a private preclinical-stage biopharmaceutical company. The firm is dedicated to developing individualized immunotherapies to combat cancer. The YGNITETM platform integrates next-generation sequencing, bioinformatics, and the proprietary CARGONAUTTM vaccine platform to deliver neoepitope peptide vaccines tailored to each patient's specific tumor.

The successful Series A funding round marks a significant milestone for YGION Biomedical, enabling them to continue their pioneering work in personalized cancer vaccines. As they progress, their innovative approach holds promise for transforming cancer treatment, making it more tailored and effective for each patient.